

# CITATION REPORT

List of articles citing

**Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures**

**DOI: 10.1111/j.0013-9580.2005.14704.x**  
**Epilepsia, 2005, 46, 31-41.**

**Source:** <https://exaly.com/paper-pdf/38244167/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
227	Antiepileptic drugs and their impact on balance. <b>2005</b> , 1, 147-155		22
226	Current awareness: Pharmacoepidemiology and drug safety. <b>2005</b> , 14, i-xii		
225	Zonisamide add-on for drug-resistant partial epilepsy. <b>2005</b> , CD001416		26
224	Zonisamide: a review of its use in the management of partial seizures in epilepsy. <b>2005</b> , 19, 347-67		30
223	New drugs in the treatment of epilepsy in children. <b>2005</b> , 35, 398-419		3
222	Zonisamide: an effective adjunctive therapy for the treatment of adults with refractory partial epileptic seizures. <b>2006</b> , 22, 1-4		
221	Anticonvulsant therapy in dogs and cats. <b>2006</b> , 36, 1107-27, vii		54
220	Modern antiepileptic drugs: guidelines and beyond. <b>2006</b> , 19, 175-80		17
219	Bibliography. Current world literature. Developmental disorders. <b>2006</b> , 19, 200-6		
218	Development of a Drosophila seizure model for in vivo high-throughput drug screening. <b>2006</b> , 24, 2211-22		62
217	A long-term follow-up of zonisamide monotherapy. <i>Epilepsia</i> , <b>2006</b> , 47, 1860-4	6.4	12
216	A role for fMRI in optimizing CNS drug development. <b>2006</b> , 5, 411-24		178
215	Introduction to zonisamide. <b>2006</b> , 68 Suppl 2, S3-9		56
214	Zonisamide as adjunctive therapy for refractory partial seizures. <b>2006</b> , 68 Suppl 2, S11-6		24
213	Practical prescribing and long-term efficacy and safety of zonisamide. <b>2006</b> , 68 Suppl 2, S17-24		27
212	New generation anticonvulsants for the treatment of epilepsy in children. <b>2006</b> , 3, 170-80		39
211	Review article: the role of anticonvulsant drugs in postoperative pain management: a bench-to-bedside perspective. <b>2006</b> , 53, 562-71		37

210	In vivo characterisation of the small-conductance KCa (SK) channel activator 1-ethyl-2-benzimidazolinone (1-EBIO) as a potential anticonvulsant. <b>2006</b> , 546, 48-53	42
209	Anxiolytic-, antidepressant- and anticonvulsant-like effects of the alkaloid montanine isolated from <i>Hippeastrum vittatum</i> . <b>2006</b> , 85, 148-54	54
208	Zonisamide for the treatment of epilepsy. <b>2006</b> , 6, 1283-92	20
207	Psychotropic effects of antiepileptic drugs. <b>2006</b> , 67, 1916-25	83
206	Efficient characterization of use-dependent ion channel blockers by real-time monitoring of channel state. <b>2006</b> , 4, 57-64	7
205	Klinische Wirksamkeit und Verträglichkeit von Zonisamid. <b>2007</b> , 34, 254-261	
204	A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. <b>2007</b> , 69, 1342-9	91
203	A new generation of anticonvulsants for the treatment of epilepsy in children. <b>2007</b> , 12, 741-4	12
202	Clinical pharmacology and mechanism of action of zonisamide. <b>2007</b> , 30, 230-40	118
201	Bibliography. Current world literature. Developmental disorders. <b>2007</b> , 20, 217-23	
200	Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. <b>2007</b> , 60, 99-102; discussion 102-3	58
199	Comparative retention rates and long-term tolerability of new antiepileptic drugs. <b>2007</b> , 16, 296-304	121
198	The cost effectiveness of zonisamide as adjunctive therapy in adult partial seizure epilepsy. <b>2007</b> , 10, 455-473	5
197	Zonisamide for bipolar depression. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 111-3	4 10
196	Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. <b>2007</b> , 75, 75-83	44
195	The main source of ambient GABA responsible for tonic inhibition in the mouse hippocampus. <b>2007</b> , 582, 1163-78	189
194	Prioritizing children's medicines for research: a pharmaco-epidemiological study of antiepileptic drugs. <b>2007</b> , 63, 689-97	42
193	Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. <i>Epilepsia</i> , <b>2007</b> , 48, 1303-7	6.4 82

192	Novel anticonvulsant drugs. <b>2007</b> , 113, 165-83		173
191	Use and safety profile of antiepileptic drugs in Italy. <b>2007</b> , 63, 409-15		17
190	[Anticonvulsant treatment with zonisamide added to topiramate. A preliminary treatment analysis in 19 patients]. <b>2007</b> , 78, 1425-9		1
189	The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?. <b>2007</b> , 64, 2090-103		213
188	[Zonisamide as add-on treatment for focal epilepsies. An outcome analysis of 74 patients]. <b>2008</b> , 79, 1416, 1418-23		1
187	Changes of cortical epileptic afterdischarges after status epilepticus in immature rats. <b>2008</b> , 78, 178-85		5
186	Inhibition of the betaine-GABA transporter (mGAT2/BGT-1) modulates spontaneous electrographic bursting in the medial entorhinal cortex (mEC). <b>2008</b> , 79, 6-13		21
185	Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy. <i>Acta Neurologica Scandinavica</i> , <b>2008</b> , 118, 87-93	3.8	26
184	Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i> , <b>2008</b> , 49, 1239-76	6.4	703
183	Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. <b>2008</b> , 17, 405-21		88
182	Use of second-generation antiepileptic drugs in the pediatric population. <b>2008</b> , 10, 217-54		30
181	Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2008</b> , 4, 493-506	5.5	42
180	A 24-year-old woman with intractable seizures: review of surgery for epilepsy. <b>2008</b> , 300, 2527-38		4
179	Antiepileptic drugs. <b>2008</b> , 30, 78-105		
178	Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. <b>2008</b> , 30, 483-9		37
177	Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release. <b>2008</b> , 4, 1035-46		30
176	Role of ventral hippocampal GABA(A) and NMDA receptors in the anxiolytic effect of carbamazepine in rats using the elevated plus maze test. <i>Pharmacology</i> , <b>2009</b> , 84, 356-66	2.3	24
175	Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. <i>Neuropsychiatric Disease and Treatment</i> , <b>2009</b> , 5, 249-59	3.1	26

174	Antiepileptic drugs to treat pain in rheumatic conditions. Recommendations based on evidence-based review of the literature and expert opinion. <b>2009</b> , 76, 75-85		9
173	Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. <b>2009</b> , 13, 3-9		28
172	Meta-analysis of the effectiveness of psychological and pharmacological treatments for binge eating disorder. <b>2010</b> , 43, 205-17		229
171	Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report. <i>Acta Neurologica Scandinavica</i> , <b>2009</b> , 120, 210-2	3.8	37
170	Clinical perspectives on lacosamide. <b>2009</b> , 9, 1-9		37
169	Zonisamide block of cloned human T-type voltage-gated calcium channels. <b>2009</b> , 83, 224-34		31
168	Les antiépileptiques dans le traitement des affections douloureuses rhumatologiques. Recommandations établies à partir d'une revue de la littérature basée sur des preuves et l'opinion d'experts. <b>2009</b> , 76, 79-90		
167	Antiepileptic drug treatment of children at a referral centre for epilepsy--does admission make a difference?. <b>2009</b> , 18, 573-9		8
166	Management of the patient with medically refractory epilepsy. <b>2009</b> , 9, 1791-802		65
165	Treatment strategies for focal epilepsy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 743-53	4	8
164	Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy. <b>2009</b> , 11, 61-6		28
163	Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development. <b>2010</b> , 3, 2090-2110		59
162	[Therapeutic drug monitoring of zonisamide]. <b>2010</b> , 65, 29-34		3
161	The evolution of antiepileptic drug development and regulation. <b>2010</b> , 12, 3-15		46
160	When the past challenges the present: are older antiepileptic drugs still the best choice in childhood absence epilepsy?. <b>2010</b> , 9, 457-9		5
159	Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. <b>2010</b> , 32, 208-12		20
158	Treatment of epilepsy in children with developmental disabilities. <b>2010</b> , 16, 239-47		31
157	Synthesis of deuterium-labelled drugs by hydrogen-deuterium (HD) exchange using heterogeneous catalysis. <b>2010</b> , 53, 686-692		33

156	Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. <b>2010</b> , 91, 273-82		42
155	Response to drug treatment in newly diagnosed epilepsy: a pilot study of (1)H NMR- and MS-based metabonomic analysis. <b>2010</b> , 88, 189-95		12
154	Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. <i>Epilepsia</i> , <b>2010</b> , 51, 7-26	6.4	105
153	Comparison of antiepileptic drug prescribing in children in three European countries. <i>Epilepsia</i> , <b>2010</b> , 51, 789-96	6.4	36
152	Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. <i>Epilepsia</i> , <b>2010</b> , 51, 921-5	6.4	29
151	Factors associated with nonbenzodiazepine antiepileptic drug intoxication: analysis of 9,809 registered cases of drug poisoning. <i>Epilepsia</i> , <b>2010</b> , 51, 979-83	6.4	8
150	Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, open-label study (ZEUS). <i>Acta Neurologica Scandinavica</i> , <b>2010</b> , 121, 141-8	3.8	18
149	Zonisamide changes unilateral cortical excitability in focal epilepsy patients. <b>2010</b> , 6, 189-95		4
148	Zonisamide as Adjunctive Therapy for Adults with Partial-Onset Epileptic Seizures: An Efficacy and Safety Review. <b>2010</b> , 2, CMT.S2710		
147	A systematic review of safety monitoring and drug toxicity in published randomised controlled trials of antiepileptic drugs in children over a 10-year period. <b>2010</b> , 95, 731-8		34
146	Antiepileptic drug response in temporal lobe epilepsy: a clinical and MRI morphometry study. <b>2010</b> , 75, 1695-701		59
145	Symptomatic and cryptogenic (probably symptomatic) focal epilepsies. <b>2010</b> , 435-496		2
144	Bone and calcium metabolism and antiepileptic drugs. <b>2010</b> , 112, 1-10		111
143	Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review. <b>2010</b> , 19, 31-5		26
142	Placebo responses in randomized trials of antiepileptic drugs. <i>Epilepsy and Behavior</i> , <b>2010</b> , 17, 64-9	3.2	35
141	A prospective audit of adjunctive zonisamide in an everyday clinical setting. <i>Epilepsy and Behavior</i> , <b>2010</b> , 17, 455-60	3.2	28
140	A Clinical Guide to Epileptic Syndromes and their Treatment. <b>2010</b> ,		71
139	The use of recently approved antiepileptic drugs: use with caution, use in refractory patients or use as first-line indications?. <b>2011</b> , 11, 1759-67		4

138	The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter?. <b>2011</b> , 25, 907-12		24
137	[Ion channel dysfunction in pathogenesis of idiopathic epilepsies]. <b>2011</b> , 45, 42-56		2
136	Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial. <b>2011</b> , 31, 221-9		16
135	The efficacy of antiepileptic drug prophylaxis in the prevention of early and late seizures following repair of intracranial aneurysms. <i>Journal of Clinical Neuroscience</i> , <b>2011</b> , 18, 1174-9	2.2	13
134	Anticonvulsant profile of the alkaloids (+)-erythravine and (+)-11-hydroxy-erythravine isolated from the flowers of <i>Erythrina mulungu</i> Mart ex Benth (Leguminosae-Papilionaceae). <i>Epilepsy and Behavior</i> , <b>2011</b> , 20, 441-6	3.2	35
133	Moderate toxic effects following acute zonisamide overdose. <i>Epilepsy and Behavior</i> , <b>2011</b> , 21, 91-3	3.2	9
132	Gastrointestinal adverse effects of antiepileptic drugs in intractable epileptic patients. <b>2011</b> , 20, 343-6		30
131	Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. <b>2011</b> , 20, 558-63		28
130	Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. <i>Epilepsia</i> , <b>2011</b> , 52, 219-33	6.4	113
129	Reversible erectile dysfunction in a patient with brain tumor-related epilepsy in therapy with zonisamide in add-on. <b>2011</b> , 8, 3515-7		16
128	Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. <b>2011</b> , 10, 961-8		206
127	Quality of life in patients with partial-onset seizures under adjunctive therapy with zonisamide: results from a prospective non-interventional surveillance study. <b>2011</b> , 13, 263-76		11
126	Zonisamide in the treatment of epilepsy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2573-81	4	24
125	Anticonvulsant activity of solasodine isolated from <i>Solanum sisymbriifolium</i> fruits in rodents. <b>2011</b> , 49, 194-9		23
124	GABA transporters as targets for new drugs. <b>2011</b> , 3, 211-22		39
123	Pharmacotherapy for children and adolescents with epilepsy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 175-94	4	17
122	Drug safety evaluation of zonisamide for the treatment of epilepsy. <b>2011</b> , 10, 623-31		17
121	New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?. <b>2011</b> , 2, 141-58		69

120	Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. <b>2012</b> , 11, 579-88		140
119	Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 1807-16	4	28
118	Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients. <b>2012</b> , 21, 188-93		8
117	Combined diazepam and HDAC inhibitor treatment protects against seizures and neuronal damage caused by soman exposure. <b>2012</b> , 33, 500-11		28
116	New approach to predicting proconvulsant activity with the use of Support Vector Regression. <b>2012</b> , 42, 575-81		5
115	Zonisamide: its pharmacology, efficacy and safety in clinical trials. <i>Acta Neurologica Scandinavica</i> , <b>2012</b> , 126, 19-28	3.8	38
114	Zonisamide in clinical practice. <i>Acta Neurologica Scandinavica</i> , <b>2012</b> , 126, 29-35	3.8	10
113	Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a medication exposure in pregnancy risk evaluation program study. <b>2012</b> , 26, 578-88		59
112	The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison. <b>2012</b> , 21, 665-78		25
111	Analgesic and anticonvulsant activity of new derivatives of 2-substituted 4-hydroxybutanamides in mice. <b>2012</b> , 64, 102-12		15
110	Approach to Sleep-Related Seizure Identification and Management. <b>2012</b> , 629-646		
109	Clinical utility of adjunctive retigabine in partial onset seizures in adults. <b>2012</b> , 8, 7-14		2
108	Synthesis and evaluation of some novel methylene-bridged aryl semicarbazones as potential anticonvulsant agents. <b>2012</b> , 21, 3797-3808		4
107	Host factors affecting antiepileptic drug delivery-pharmacokinetic variability. <b>2012</b> , 64, 896-910		66
106	Carbamazepine potentiates morphine analgesia on postoperative pain in morphine-dependent rats. <b>2012</b> , 674, 332-6		11
105	Placebo-corrected efficacy of modern nonenzyme-inducing AEDs for refractory focal epilepsy: systematic review and meta-analysis. <i>Epilepsia</i> , <b>2012</b> , 53, 512-20	6.4	14
104	Study on the interaction of the epilepsy drug, zonisamide with human serum albumin (HSA) by spectroscopic and molecular docking techniques. <b>2013</b> , 114, 627-32		75
103	Zonisamide: a review of its use in the management of adults with partial seizures. <b>2013</b> , 73, 1321-38		14



102	How clinically useful are regulatory trials with new antiepileptic drugs?. <b>2013</b> , 1, 21-24		2
101	Neuronal degeneration is observed in multiple regions outside the hippocampus after lithium pilocarpine-induced status epilepticus in the immature rat. <b>2013</b> , 252, 45-59		40
100	The adverse event profile of zonisamide: a meta-analysis. <i>Acta Neurologica Scandinavica</i> , <b>2013</b> , 128, 297-304		15
99	Management and monitoring of patients treated with zonisamide: the OZONE study. <b>2013</b> , 15, 278-88		9
98	Investigation of influencing factors on higher placebo response in East Asian versus Western clinical trials for partial epilepsy: a meta-analysis. <b>2013</b> , 33, 315-24		5
97	Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials. <b>2013</b> , 76, 649-67		38
96	Glial cell changes in epilepsy: overview of the clinical problem and therapeutic opportunities. <b>2013</b> , 63, 638-51		23
95	Actualizaci3n de las gu3as para el tratamiento farmacol3gico de la epilepsia en adultos. <b>2013</b> , 5, 187-198		
94	Glial cells as primary therapeutic targets for epilepsy. <b>2013</b> , 63, 635-7		12
93	Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal. <b>2013</b> , 31, 101-10		29
92	Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2013</b> , 9, 105-15	5.5	27
91	Dibenzazepine-Based Sodium Channel Blockers for the Treatment of Neuropathic Pain. <b>2013</b> , 115-133		0
90	Effects of sodium butyrate on methamphetamine-sensitized locomotor activity. <b>2013</b> , 239, 139-47		11
89	Zonisamide add-on for drug-resistant partial epilepsy. <i>The Cochrane Library</i> , <b>2013</b> , CD001416	5.2	10
88	[Combination therapy for epilepsy]. <b>2013</b> , 81, 9-20		2
87	The Evaluation of Patients Admitted to the Emergency Department with Non-Benzodiazepine Antiepileptic Drug Poisoning. <b>2013</b> , 12, 199-204		
86	Epilepsy, antiseizure therapy, and sleep cycle parameters. <b>2013</b> , 2013, 670682		19
85	Safety and tolerability of zonisamide in elderly patients with epilepsy. <i>Acta Neurologica Scandinavica</i> , <b>2013</b> , 128, 422-8	3.8	17

- 84 Safety and tolerability of perampanel: a review of clinical trial data. *Acta Neurologica Scandinavica*, **2013**, 127, 30-5 3.8 15
- 83 Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults. **2013**, 7, 397-402 7
- 82 Zonisamide. 314-324
- 81 Chronotherapy in the treatment of epilepsy. **2014**, 109 0
- 80 A review of safety and efficacy of zonisamide for treatment of pediatric partial epilepsy. **2014**, 155
- 79 Newer drug treatments for focal-onset epilepsy. **2014**, 10, 6-12
- 78 Biochemical and Surgical Aspects of Epilepsy Related to Brain Tumors [Appraising Redox Biology and Treatments. **2014**,
- 77 Safety considerations for patients with epilepsy taking antiepileptic drugs alongside caffeine or other methylxanthine derivatives. *Expert Opinion on Drug Metabolism and Toxicology*, **2014**, 10, 981-9 5.5 13
- 76 Advances in epilepsy treatment: lacosamide pharmacokinetic profile. **2014**, 1329, 18-32 40
- 75 A pharmaco-EEG-based assessment of the interaction between ethanol and zonisamide. **2014**, 49, 505-14 3
- 74 Investigation of the effects of Zn<sup>2+</sup>, Ca<sup>2+</sup> and Na<sup>+</sup> ions on the interaction between zonisamide and human serum albumin (HSA) by spectroscopic methods. **2014**, 122, 48-54 14
- 73 Zonisamide as a treatment for partial epileptic seizures: a systematic review. **2014**, 31, 276-88 12
- 72 Antiepileptic drug use in seven electronic health record databases in Europe: a methodologic comparison. *Epilepsia*, **2014**, 55, 666-673 6.4 30
- 71 Untangling the pathomechanisms of temporal lobe epilepsy--the promise of epileptic biomarkers and novel therapeutic approaches. **2014**, 109, 1-12 6
- 70 Zonisamide. **2015**, 680-688
- 69 Zonisamide: Review of Recent Clinical Evidence for Treatment of Epilepsy. **2015**, 21, 683-91 22
- 68 Neuroprotective agents and modulation of temporal lobe epilepsy. **2015**, 7, 79-93 9
- 67 Synergistic effect of docosahexaenoic acid on anticonvulsant activity of valproic acid and lamotrigine in animal seizure models. **2015**, 388, 1029-38 9

66	Pain Management and Palliative Care. <b>2015</b> ,		1
65	Retention rate of zonisamide in intractable epilepsy. <i>Acta Neurologica Scandinavica</i> , <b>2015</b> , 131, 268-74	3.8	9
64	Dried blood spots for monitoring and individualization of antiepileptic drug treatment. <b>2015</b> , 75, 25-39		32
63	Antiepileptic Drugs: First Generation. <b>2015</b> , 159-169		
62	Antiepileptic Drugs. <b>2015</b> , 171-193		
61	Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. <b>2015</b> , 54, 901-14		64
60	Time to prerandomization monthly seizure count in perampanel trials: A novel epilepsy endpoint. <b>2015</b> , 84, 2014-20		19
59	Evaluation of safety and efficacy of zonisamide in adult patients with partial, generalized, and combined seizures: an open labeled, noncomparative, observational Indian study. <b>2016</b> , 12, 327-34		3
58	Paracetamol decreases steady-state exposure to lamotrigine by induction of glucuronidation in healthy subjects. <b>2016</b> , 81, 735-41		8
57	Could Adult European Pharmacoresistant Epilepsy Patients Be Treated With Higher Doses of Zonisamide?. <b>2016</b> , 39, 121-4		1
56	Influence of caffeine on the protective activity of gabapentin and topiramate in a mouse model of generalized tonic-clonic seizures. <b>2016</b> , 68, 680-5		13
55	A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. <b>2016</b> , 86, 1729-35		46
54	Impact of varying outcomes and definitions of suicidality on the associations of antiepileptic drugs and suicidality: comparisons from UK Clinical Practice Research Datalink (CPRD) and Danish national registries (DNR). <b>2016</b> , 25 Suppl 1, 142-55		10
53	Types of Epilepsy. <b>2016</b> , 75-92		2
52	Therapeutic Targets and Future Directions. <b>2016</b> , 343-366		
51	Efficacy and Tolerability of Antiepileptic Drugs in Patients with Focal Epilepsy: Systematic Review and Network Meta-analyses. <b>2016</b> , 36, 1255-1271		26
50	Three-Dimensional Printing of Carbamazepine Sustained-Release Scaffold. <b>2016</b> , 105, 2155-63		40
49	Changing the approach to treatment choice in epilepsy using big data. <i>Epilepsy and Behavior</i> , <b>2016</b> , 56, 32-7	3.2	32

48	Antiepileptic Drugs. <b>2016</b> , 155-177		0
47	Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: Results of the observational study ZOOM. <b>2016</b> , 34, 66-73		9
46	Antiepileptic Drug Therapy: Management Issues and Pregnancy. <b>2016</b> , 193-213		
45	Antiepileptic Drugs and Pregnancy. <b>2016</b> ,		1
44	Evaluate the Efficacy and Safety of Anti-Epileptic Medications for Partial Seizures of Epilepsy: A Network Meta-Analysis. <b>2017</b> , 118, 2850-2864		11
43	Caffeine Protects Against Anticonvulsant-Induced Neurotoxicity in the Developing Rat Brain. <b>2017</b> , 32, 460-472		10
42	Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis. <b>2017</b> , 7, 2535		24
41	Individualizing Antiepileptic Therapy for Patients. <b>2017</b> , 327-371		
40	Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption. <b>2018</b> , 70, 384-411		168
39	A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures. <b>2018</b> , 26, 1125-1131		7
38	Vitamin D supplementation for bone health in adults with epilepsy: A systematic review. <i>Epilepsia</i> , <b>2018</b> , 59, 885-896	6.4	14
37	Age-dependent behaviors, seizure severity and neuronal damage in response to nerve agents or the organophosphate DFP in immature and adult rats. <b>2018</b> , 66, 10-21		17
36	Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices. <b>2018</b> , 103, 1093-1099		10
35	Effect of zonisamide on refractory epilepsy during pregnancy in lamotrigine resistant kindled rats. <b>2018</b> , 664, 91-97		3
34	Zonisamide add-on therapy for focal epilepsy. <i>The Cochrane Library</i> , <b>2018</b> , 10, CD001416	5.2	4
33	Clinically indicated electrical stimulation strategies to treat patients with medically refractory epilepsy. <b>2018</b> , 3, 198-209		4
32	Pharmacokinetics in Plants: Carbamazepine and Its Interactions with Lamotrigine. <b>2018</b> , 52, 6957-6964		25
31	Perampanel: Does it have broad-spectrum potential?. <i>Epilepsia</i> , <b>2019</b> , 60 Suppl 1, 22-36	6.4	23

30	Involvement of the L-arginine/Nitric Oxide/Cyclic GMP/KATP Channel Pathway and PPAR $\alpha$ Receptors in the Peripheral Antinociceptive Effect of Carbamazepine. <b>2019</b> , 69, 650-657		8
29	Interaction between paracetamol and lamotrigine: new insights from the FDA Adverse Event Reporting System (FAERS) database. <b>2019</b> , 75, 1323-1325		4
28	Estimation of apparent clearance of valproic acid in adult Saudi patients. <b>2019</b> , 41, 1056-1061		4
27	Estimation of Phenytoin Pharmacokinetic Parameters in Saudi Epileptic Patients. <i>Pharmacology</i> , <b>2019</b> , 104, 60-66	2.3	3
26	An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 909-915	4	15
25	Transformation of lamotrigine by white-rot fungus <i>Pleurotus ostreatus</i> . <i>Environmental Pollution</i> , <b>2019</b> , 250, 546-553	9.3	12
24	Epilepsy as a dynamical system, a most needed paradigm shift in epileptology. <i>Epilepsy and Behavior</i> , <b>2021</b> , 121, 106838	3.2	2
23	Efficacy, tolerability, and blood concentration of zonisamide in daily clinical practice. <i>Journal of Clinical Neuroscience</i> , <b>2019</b> , 61, 44-47	2.2	2
22	Effects of zonisamide monotherapy on bone health in drug-naive epileptic patients. <i>Epilepsia</i> , <b>2020</b> , 61, 2142-2149	6.4	1
21	Zonisamide add-on therapy for focal epilepsy. <i>The Cochrane Library</i> , <b>2020</b> , 7, CD001416	5.2	1
20	Changes in cognition after introduction or withdrawal of zonisamide versus topiramate in epilepsy patients: A retrospective study using Bayes statistics. <i>Epilepsia</i> , <b>2020</b> , 61, 1481-1490	6.4	7
19	Evaluation of zonisamide for the treatment of focal epilepsy: a review of pharmacokinetics, clinical efficacy and adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 169-177	5.5	3
18	Long-term effects of zonisamide in adult patients with intellectual disability. <i>Acta Neurologica Scandinavica</i> , <b>2021</b> , 144, 275-282	3.8	1
17	A meta-analysis: efficacy and safety of anti-epileptic drugs prescribed in Korea as monotherapy and adjunctive treatment for patients with focal epilepsy. <i>Translational and Clinical Pharmacology</i> , <b>2021</b> , 29, 6-20	2	2
16	Safety and Efficacy of Zonisamide in Patients with Epilepsy: A Post-Marketing Surveillance Study. <i>Journal of Epilepsy Research</i> , <b>2015</b> , 5, 89-95	1.8	4
15	Zonisamide - a review of experience and use in partial seizures. <i>Neuropsychiatric Disease and Treatment</i> , <b>2006</b> , 2, 269-80	3.1	29
14	Zonisamid. <b>2007</b> , 29,		0
13	Zone of electrical stimulation induced seizures in subdural electrodes. <b>2008</b> , 746-750		

- 12 Zonisamide. **2010**, 1877-1881
- 11 Binge-Eating-Störung. **2011**, 203-221
- 10 Antiepileptic Medications. **2011**, 678-683
- 9 Further Reading. 378-407
- 8 Second Generation Anticonvulsants: Gabapentin, Lamotrigine, Levetiracetam, and Topiramate. **2016**, 1-18
- 7 Second Generation Anticonvulsants: Gabapentin, Lamotrigine, Levetiracetam, and Topiramate. **2017**, 1065-1081
- 6 Second Generation Anticonvulsants: Gabapentin, Lamotrigine, Levetiracetam, and Topiramate. **2017**, 1-18
- 5 [A retrospective analysis of using zonisamide and retention in monotherapy among patients with epilepsy in routine clinical practice]. *Zhurnal Nevrologii I Psikhatrii Imeni S S Korsakova*, **2019**, 119, 80-87 <sup>0.4</sup>
- 4 Abnormal Behavior Episodes Associated With Zonisamide in Three Dogs: A Case Report. *Frontiers in Veterinary Science*, **2021**, 8, 763822 3.1 ○
- 3 Anticonvulsant Agents: Zonisamide. **2020**, 1-15
- 2 New generation anticonvulsants for the treatment of epilepsy in children. *Neurotherapeutics*, **2006**, 3, 170-180 6.4
- 1 Treatment of Focal-Onset Seizures in Children: Should This Be More Etiology-Driven?. *Frontiers in Neurology*, **2022**, 13, 842276 4.1 ○